Overview

Bioequivalence Study for Acarbose/Metformin FDC

Status:
Completed

Trial end date:
2020-03-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the bioequivalence (i.e. similar pharmacokinetics and pharmacodynamics characteristics) between acarbose/metformin FDC (50 mg/500 mg) and loose combination of acarbose (50 mg) and metformin (500 mg)

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Acarbose
Metformin